

Company That just Released World's First Saliva Test for Autism Opens Up Investment Opportunity to the Public

Quadrant Biosciences offers common shares through equity crowdfunding platform

SYRACUSE, NEW YORK, UNITED STATES, March 31, 2020 /EINPresswire.com/ -- Company That just Released World's First Saliva Test for Autism Opens Up Investment Opportunity to the Public

[Quadrant Biosciences](#) offers common shares through equity crowdfunding platform


Quadrant Biosciences Inc ("Quadrant Biosciences"), a leading developer of epigenetic diagnostic solutions, including the world's first saliva test for

autism, announced that it is now offering common shares of the company (at a price of \$3/share, with a minimum investment of \$300) through equity crowdfunding platform [Wefunder](#). The Reg A plus campaign is Quadrant's first offering of common shares to the public -- the company has previously raised over \$32 million through private sales of its common shares to accredited investors only.

Quadrant Biosciences is a life science company that leverages new discoveries in the field of epigenetics and microbiome research to develop novel diagnostic solutions to many of today's critical health care challenges. In December, the company commercially released [Clarifi ASD™](#), the first of its kind epigenetic saliva test to aid the diagnosis of autism in children 18 months through six years of age. Quadrant Biosciences collaborated with researchers from SUNY Upstate Medical University and Penn State College of Medicine to create this novel biological test that is based on the genetic sequencing and molecular analysis of regulatory RNAs and microbes in the saliva.

Clarifi ASD™ is the first product to be launched from the company's Clarifi™ Epigenetic Diagnostic Platform. According to Quadrant CEO and Founder Richard Uhlig, several other tests using the same epigenetic research and next-generation sequencing technology are currently under research and development. "Our collaborative research with SUNY Upstate Medical and Penn State College of Medicine has shown that the same approach we used for developing the Clarifi autism saliva test - evaluating epigenetic molecules found in the saliva - is demonstrating similar diagnostic utility for other neurological diseases such as Parkinson's Disease and Concussion Injuries. It is exciting and extremely gratifying to be on the forefront of these life-changing discoveries."

Prospective investors interested in learning more about Quadrant Biosciences and the



investment opportunity can review offering documents and other information about the company at <https://www.quadrantbiosciences.com/investor-relations/>

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM HERE. YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.

See the NCPS Offerings Disclosure here.

Securities offered through North Capital Private Securities, member FINRA/SIPC.

Investment risk - liquidity, risk of loss; Not tax, investment, accounting advice; past performance not indicative of future results; consult with a professional (attorney, advisor, accountant); conduct your own research and due diligence; forward looking statements; information believed to be correct but don't rely upon it / no warranty; not an offer to sell securities; information may not be complete; investments not suitable for all investors; not a recommendation; platforms are not brokers; member FINRA and SIPC

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY'S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS "ESTIMATE," "PROJECT," "BELIEVE," "ANTICIPATE," "INTEND," "EXPECT" AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

About Quadrant Biosciences

Quadrant Biosciences is a life science company involved in the development of functional assessments and epigenetic diagnostic solutions for large-scale health issues. The company has entered into collaborative research relationships with a number of institutions including SUNY Upstate Medical University and Penn State University to explore and develop novel biomarker technologies with a focus on Autism Spectrum Disorder, concussion, and Parkinson's Disease. Quadrant Biosciences also participates in the Start-up NY program, a New York State economic development program. For more information, please visit www.quadrantbiosciences.com.

David MacLean
Quadrant Biosciences
+1 315-614-2325

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.